NOMAD POWER SOLUTIONS, INC.

We are a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. Our product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which are used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. We believe that inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. We are focusing on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity.

1. Regulation FD DisclosureOct 6, 2026
2. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesSep 30, 2026
3. Financial Statements and ExhibitsSep 17, 2026
4. 10-Q filingAug 14, 2026
5. SCHEDULE 13G - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding NOMAD POWER SOLUTIONS, INC.Jul 31, 2026